FOLFOX4 方案二线治疗晚期胃癌的临床观察

  目的 评价奥沙利铂联合亚叶酸钙和5氟脲嘧啶组成的FOLFOX4方案二线治疗晚期胃癌的有效性及安全性。方法 34例经过紫杉类药物为主方案治疗后失败的晚期胃癌患者，给予FOLFOX4方案化疗，治疗后按WHO标准进行评价。结果 全组34例，可评价疗效的有33例，其中CR1例，PR6例，SD14例，PD12例，RR率为21．2％，中位缓解时间5个月，中位TTP4．2个月，中位生存期6个月；可评价毒性的有34例，毒副反应主要是骨髓抑制、恶心、呕吐等消化道反应及外周感觉神经毒性，经对症处理，可以逆转。结论 FOLFOX4方案二线治疗晚期胃癌疗效肯定，安全性较好，值得深入研究。

Study of Oxaliplatin Combined with 5-fluorouracil and Folinic Acid (FOLFOX 4 regimen) as Second Line Treatment for the Patients with Advanced Gastric Cancer

Objective To evaluate the effect and toxicity of oxaliplatin combined with 5-fluorouracil and folinic acid (FOLFOX4 regimen) as second-line treatment for the patients with advanced gastric cancer(AGC). Methods 34 cases with advanced gastric cancer and received Taxane regimen chemotherapy before, were treated with FOLFOX4 regimen. Results 33 patients were evaluated for clinical response. The overall response rate was 21.2% (CR 1, PR 6, SD 14 and PD 12). The median duration of response was 5 months. Median TTP was 4.2 months. Median survival time was 6 months. 34 patients were evaluated for toxicity. The major reaction was bone suppression, nausea/vomiting and peripheral nerve toxicity. Conclusion The FOLFOX4 regimen is an active and good regimen as the second line treatment for AGC, with favorable toxicity profile and deserves further evaluation in randomized studies.